GleamWall
中文EN

CRBU Caribou Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1619856 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.6%
TTM net income YoY34.8%
TTM EPS YoY39.4%
Revenue 3-yr CAGR-35.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,140.6%
Net margin-1,085.0%
FCF margin-984.6%
EBITDA margin-1,113.6%

Returns

ROE-93.8%
ROA-64.4%
ROIC (approx.)-93.9%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets37.7%
Debt / equity0.00x
Current ratio4.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue-1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.61M$1.50M$2.40M$3.94M$2.20M$2.67M$2.35M$2.08M
R&D expense$21.35M$18.94M$20.61M$23.82M$22.40M$27.69M$35.53M$30.46M
SG&A expense$7.90M$7.90M$8.07M$8.58M$9.20M$10.40M$9.73M$10.49M
Operating income-$27.64M-$25.34M-$26.28M-$28.45M-$29.40M-$47.58M-$42.91M-$38.88M
Income tax——$0-$550,000$0—$0-$9,000
Net income-$26.61M-$24.28M-$25.09M-$26.49M-$27.55M-$54.10M-$39.99M-$35.49M
EBITDA-$27.05M-$24.71M-$25.63M-$27.77M-$28.77M-$46.41M-$41.75M-$37.69M
EPS (basic)-0.25-0.24-0.26—-0.30-0.58-0.43—
EPS (diluted)-0.25-0.24-0.26—-0.30-0.58-0.43—
Weighted avg. shares (diluted)107.54M100.99M95.86M—93.29M93.03M92.68M—
Balance sheet
Cash & equivalents$26.06M$26.19M$12.06M$12.36M$11.14M$25.20M$29.42M$16.34M
Short-term investments$68.74M$86.12M$105.57M$126.98M$136.12M$158.75M$179.05M$193.24M
Receivables$518,000$203,000$227,000$69,000$242,000$71,000$88,000$265,000
Current assets$100.08M$116.59M$122.38M$145.23M$155.51M$192.51M$217.32M$219.38M
PP&E, net$4.87M$5.50M$6.12M$6.76M$7.60M$8.18M$18.52M$19.28M
Total assets$123.03M$142.77M$149.00M$175.37M$194.98M$220.90M$273.66M$313.31M
Current liabilities$20.14M$17.97M$19.67M$25.41M$28.06M$28.89M$28.49M$30.65M
Total liabilities$46.39M$44.67M$46.98M$53.19M$53.14M$54.77M$56.43M$60.36M
Shareholders' equity$76.63M$98.10M$102.02M$122.17M$141.84M$166.13M$217.22M$252.95M
Shares outstanding108.04M106.00M96.95M95.14M93.47M93.12M93.00M92.38M
Cash flow statement
Operating cash flow-$22.52M-$22.79M-$26.98M-$20.82M-$25.18M-$28.26M-$36.73M-$35.47M
Capital expenditure$19,000$1,000$72,000-$216,000$115,000$418,000$1.04M$518,000
Free cash flow-$22.54M-$22.79M-$27.06M-$20.61M-$25.30M-$28.68M-$37.77M-$35.99M
Investing cash flow$19.39M$18.94M$23.98M$17.97M$10.85M$24.04M$49.38M$15.93M
Financing cash flow$2.99M$17.94M$2.70M$4.07M$277,000$6,000$468,000$3.86M
Depreciation & amortization$590,000$625,000$649,000$682,000$631,000$1.17M$1.17M$1.18M
Stock-based compensation$2.16M$2.48M$2.36M$2.74M$2.93M$3.13M$3.88M$3.91M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.